Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Net Loss Per Share

Note 15 - Net Loss Per Share

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Earnings Per Share [Text Block]

15. Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:

	*Three Months Ended*
	*March 31,*
	*2024*			*2023*
Numerator:
Net loss applicable to common stockholders, basic and diluted	$	(3,429	)	$	(4,389	)

Denominator:
Weighted-average number of shares, basic and diluted		17,419			13,296

Net loss per share, basic and diluted	$	(0.20	)	$	(0.33	)

The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	*Three Months Ended*
	*March 31,*
	*2024*		*2023*
Options to purchase common stock		197		268
Restricted stock units		1,133		1,029
Warrants for common stock		1,240		1,240
Total common stock equivalents		2,570		2,537